Probi (PROB.ST) Aandeel Koers
Probi Koers
De omzet is de afgelopen 19 jaar met 12,8% per jaar gegroeid tot 627,69 Miljoen SEK. De winst per aandeel is de afgelopen 19 jaar met 3,7% per jaar gegroeid. De nettowinstmarge van Probi ligt op 2,7% en is ten opzichte van 13,7% enkele jaren eerder gedaald. Probi biedt momenteel een dividendrendement van circa 0,37%. De uitkeringsratio ligt rond 88% van de winst. Het dividend is de afgelopen 13 jaar met 8,1% per jaar gegroeid.
Probi aandeelkoers
Deze data ophalen via de Eulerpool API
100.000 requests/maand gratis · geen creditcard
Probi bedrijfsmodel & aandelenanalyse
Veelgestelde vragen over Probi
The business model of Probi AB focuses on developing, producing, and selling highly researched and scientifically proven probiotic products. Probi AB specializes in developing strains of live bacteria that promote health and well-being. These strains are then incorporated into a wide range of products, including dietary supplements, functional foods, and medical devices. The company collaborates with leading universities and research institutes to ensure the efficacy and safety of its products. Probi AB's business model emphasizes innovation, quality, and consumer trust, making it a market leader in the probiotics industry.
Probi AB is primarily active in the industries of probiotics, dietary supplements, and functional foods. As a leading provider in the market, Probi AB specializes in developing and manufacturing innovative and science-based probiotic solutions. With a focus on promoting digestive and immune health, the company offers a wide range of products that cater to both consumers and professionals in the healthcare industry. Probi AB's expertise and dedication to quality have established them as a trusted name in the probiotics industry, making them a go-to choice for individuals and businesses seeking reliable and effective probiotic solutions.
The main competitors of Probi AB in the market include companies like Chr. Hansen Holding A/S, DuPont de Nemours, Inc., and Nestlé S.A. These competitors also operate within the probiotics industry and offer similar products and services. However, it is worth noting that Probi AB has established a strong market presence with its innovative probiotic solutions and unique formulations. As a leading player in the market, Probi AB continues to strive for excellence and differentiation, further solidifying its position in the competitive landscape.
Probi AB is a Swedish biotechnology company specializing in probiotics and beneficial bacteria. Founded in 1991, the company has a rich history of innovation in the field of probiotic research. Probi AB has been at the forefront of developing and supplying clinically proven probiotic products to promote gut health and overall well-being. With a strong emphasis on research and development, Probi AB has established itself as a trusted global leader in the probiotics industry. Continually expanding their portfolio, Probi AB has partnered with numerous companies to bring their high-quality probiotic solutions to consumers worldwide.
Probi AB, a leading biotechnology company, has achieved several significant milestones. With their dedication to research and innovation, Probi AB has made notable advancements in the field of probiotics. These include the development of clinically documented strains and the expansion of their product portfolio. Probi AB has also successfully collaborated with renowned partners to enhance their offerings and reach a wider market. Moreover, the company has focused on expanding its global footprint, establishing a strong presence in key regions. Through these achievements, Probi AB continues to solidify its position as a trusted provider of high-quality probiotics for improved health and well-being.
Probi AB, a leading company in the field of probiotics, is primarily present in various countries and regions worldwide. With its headquarters in Lund, Sweden, Probi AB has established a strong global presence. The company's operations span across key markets, including Europe, North America, and Asia. Probi AB's commitment to delivering high-quality probiotic solutions has led to collaborations with numerous partners and the availability of its products in multiple international markets. This global reach enables Probi AB to bring the benefits of probiotics to a diverse range of consumers, enhancing their health and well-being.
Probi AB represents strong values and a solid corporate philosophy. The company focuses on enhancing people's health and well-being through innovative probiotic solutions. Probi AB is dedicated to delivering high-quality products that are supported by extensive research and scientific expertise. With a commitment to transparency and ethical standards, the company aims to create sustainable value for its stakeholders. Probi AB values continuous improvement, collaboration, and a customer-centric approach. By leveraging their expertise in probiotics, Probi AB strives to make a positive impact on people's lives and contribute to a healthier future.
Omgezet tegen de huidige wisselkoers noteert het aandeel Probi op 31,56 EUR (348,00 SEK).
Het aandeel Probi (PROB.ST) is genoteerd aan 5 beurzen, waaronder: London (0GZB.L), Stockholm (PROB.ST).
Probi AB is a Swedish company specializing in the development and marketing of probiotics. The company was founded in 1991 and is headquartered in Lund, Sweden. Probi AB is a pioneer in the field of probiotics and has achieved a leading position in recent years. The company utilizes its expertise in microbiology, clinical research, production, and distribution to bring innovative products to the market. Probi AB's business model focuses on the production and marketing of probiotics, which are live microorganisms that can have a positive effect on health when consumed in sufficient quantities. The company offers a wide range of probiotic products, including those for immune system strengthening, digestion, skin health, and overall health and well-being. Key areas of Probi AB's product range include the development, manufacturing, and marketing of probiotic products for various target groups. This includes dietary supplements, foods and beverages with probiotic ingredients, as well as probiotic bacterial strains for use in medications and cosmetic products. A significant area of Probi AB's product range is the development of probiotic dietary supplements, which contain a high concentration of probiotic bacterial strains that can be specifically used to address certain health issues. These dietary supplements are marketed under various brands and are available in different forms, including capsules, tablets, and powders. Probi AB also offers probiotic foods and beverages that are available in supermarkets and drugstores. These products typically contain a lower concentration of probiotic bacteria and are intended for general use. Examples include yogurts, dairy products, fruit juices, and cereal bars. In addition to probiotic foods and dietary supplements, Probi AB also provides probiotic bacterial strains for medical use. These strains are used in the development of medications that can be used to treat various conditions, including gastrointestinal problems, skin disorders, and infections. In conclusion, Probi AB's business model is based on the development and marketing of probiotics. The company offers a comprehensive range of probiotic products suitable for different target groups. Probi AB is a leading provider of probiotics and utilizes its expertise to bring innovative products to the market and promote awareness of the benefits of probiotics.
De verwachte omzet van Probi bedraagt 703,50 Miljoen SEK. Deze cijfers zijn gebaseerd op huidige financiële gegevens en weerspiegelen de bedrijfsresultaten van het bedrijf.
De verwachte winst van Probi bedraagt 69,08 Miljoen SEK. De nettowinst weerspiegelt de rentabiliteit van het bedrijf na aftrek van alle kosten.
De koers-winstverhouding (P/E) van Probi bedraagt momenteel 57,40. De P/E-ratio vergelijkt de huidige aandeelkoers met de winst per aandeel en helpt beleggers de waardering van het Probi-aandeel in te schatten.
De koers-omzetverhouding (P/S) van Probi bedraagt momenteel 5,64. De P/S-ratio vergelijkt de marktkapitalisatie met de jaarlijkse opbrengsten en dient als waarderingsmaatstaf voor het Probi-aandeel.
De Eulerpool Kwaliteitsscore voor Probi is 3/10.
De ISIN van Probi is SE0001280355. De ISIN (International Securities Identification Number) is een wereldwijd unieke identificatie voor wertpapieren.
De WKN van Probi is A0JKFA. De WKN (Wertpapierkennnummer) is een zescijferig Duits identificatienummer voor wertpapieren.
Het tickersymbool van Probi is PROB.ST. Onder dit beurstickersymbool wordt het Probi-aandeel op de beurs verhandeld.
Probi aandeel
Probi Peer Group
Probi Ticker
Probi FIGI
Alle fundamentals en diepgaande analyse van Probi
Onze aandelenanalyse van het Probi-aandeel omvat belangrijke financiële kerncijfers zoals de omzet, de winst, de P/E-ratio, de P/S-ratio, de EBIT, evenals informatie over het dividend. Daarnaast bekijken we aspecten zoals aandelen, marktkapitalisatie, schulden, eigen vermogen en verplichtingen van Probi. Als u meer gedetailleerde informatie zoekt over deze onderwerpen, bieden we op onze subpagina's uitgebreide analyses: